Finch Therapeutics and Eloxx Pharmaceuticals Compared

A look at the financial metrics and product pipelines of the two biotech companies.

Feb. 1, 2026 at 9:31pm

Got story updates? Submit your updates here. ›

This article compares the top-line revenue, earnings per share (EPS), valuation, net margins, return on equity, return on assets, and stock price volatility of Finch Therapeutics Group and Eloxx Pharmaceuticals, two clinical-stage biotech companies. It also provides an overview of the product pipelines and business focus areas for each company.

Why it matters

The comparison highlights the relative financial performance and product development progress of the two biotech firms, which could be useful information for investors and industry analysts tracking the competitive landscape in the pharmaceutical and biotechnology sectors.

The details

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating it is currently the more affordable of the two stocks. Finch Therapeutics has a beta of 1.17, suggesting its stock price is 17% more volatile than the S&P 500, while Eloxx Pharmaceuticals has a beta of -1686.44, implying its stock is 168,744% less volatile than the broader market index. Finch Therapeutics is developing microbiome-based therapeutics, including candidates for autism spectrum disorder, ulcerative colitis, and Crohn's disease. Eloxx Pharmaceuticals is focused on rare and ultra-rare genetic diseases, with its lead drug ELX-02 in Phase 2 trials for cystic fibrosis and nephropathic cystinosis.

  • The article was published on February 2, 2026.

The players

Finch Therapeutics Group

A clinical-stage microbiome therapeutics company developing treatments for conditions like autism spectrum disorder, ulcerative colitis, and Crohn's disease.

Eloxx Pharmaceuticals

A clinical-stage biopharmaceutical company focused on developing treatments for rare and ultra-rare genetic diseases, with a lead drug candidate ELX-02 in Phase 2 trials.

Got photos? Submit your photos here. ›

The takeaway

The comparison of Finch Therapeutics and Eloxx Pharmaceuticals highlights the different therapeutic focus areas and financial profiles of the two clinical-stage biotech companies, providing investors and analysts with insights into the competitive dynamics within the pharmaceutical industry.